This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/11/2020
Ladies and gentlemen, thank you for standing by and welcome to the Q3 2020 Solaris Pharmaceuticals earnings webcast and conference call. At this time, all participants are on the listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star and zero. I would now like to hand the conference over to your speaker today, to Mr. Jason Randall, T Brand strategic advisor. Thank you. Please go ahead, sir.
Good afternoon, everyone. And thank you for joining today's 2020 third quarter financial and corporate results call. Earlier this afternoon, Solaris Pharmaceuticals issued a press release detailing its financial results for the three months ended September 30th, 2020, which we encourage listeners to read. The press release can be found in the news section of solarispharma.com. Solaris will also file a 10-Q tomorrow morning before market open, and the 10-Q will be available on solarispharma.com and sec.gov. Before beginning today's call, I would like to make the following statement. Today we'll be making forward-looking statements about future expectations, plans, events, and circumstances including statements about our strategy, future operations, the development of our lead investigational drug candidate, secludamstat, including statements related to study results and our expectations regarding our capital allocation and cash resources. These statements are based on current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainty. including those detailed in the risk factors section of Solaris Pharmaceuticals 10Q file with the SEC and other filings we make with the SEC from time to time. Solaris Pharmaceuticals disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. Joining me on today's call is David Arthur, Director and CEO of Solaris Pharmaceuticals. who will provide an update on Solaris' corporate and clinical achievements during the third quarter and its vision for the future. And Mark Rosenblum, CFO, will review Solaris' third quarter 2020 financial results. David, go ahead.
Thank you, Jason, and thank you to everyone joining our conference call this afternoon, including all of you joining for the first time. 2020 continues to be an exciting year for Solaris. And events during the third quarter illustrate the significant progress Solaris has made, affirming our growth strategy and highlighting the opportunity that Seclodemstat offers as a potential treatment for pediatric cancers, solid tumors, and other cancers. For those of you participating for the first time, let me take a moment to describe Solaris. In a nutshell, we are developing new medicines for patients who need them the most. Solaris is a clinical stage biopharmaceutical company developing potential treatments for children and adults with pediatric cancer, solid tumors, and other cancers. We are currently treating patients with our investigational new oral drug, seclidemstat, in two clinical trials to explore its potential as a treatment for multiple types of cancers. Our lead clinical program is Ewing Sarcoma. a rare and devastating bone and soft tissue pediatric cancer, which is the second most common tumor among children and adolescents. Patients diagnosed with metastatic Ewing sarcoma or cancer that has already spread at the time of diagnosis have five-year survival rates between only 18 and 30 percent. The prognosis for patients with recurrent Ewing sarcoma is particularly poor. The five-year survival after a recurrence of Ewing is approximately 10 to 15%. And unfortunately, the median age of diagnosis of patients with Ewing is only 15 years of age. As a potential twice-daily oral treatment that is not a cytotoxic agent, meaning seclidemstat is not chemotherapy, Ceclodemstat represents a potential breakthrough, a breakthrough in the treatment of select pediatric cancers. With that as a backdrop, let's now talk about the third quarter. There were several important events that provided bookends to what has been an active three-plus months for Solaris. In July, we welcomed Dr. Nadeem Mirza as our Senior Vice President of Clinical Development. Since his hire, Dr. Mirza has been instrumental in advancing our clinical programs in Ewing sarcoma and solid tumors, as well as identifying potential opportunities to grow our secludemstat pipeline. In this regard, in July, we announced plans to expand our ongoing Ewing clinical trial to include patients with sarcomas that share a similar biology to Ewing sarcoma. As part of that announcement, we highlighted a refractory Ewing sarcoma patient who was treated with seclidemstat for six months and demonstrated a reduction of over 80% in their prospectively defined target lesions. Target lesions generally represent a patient's largest measurable tumors. We believe this is a remarkable result given the extreme challenges of the disease and the fact that this patient was treated with single-agent seclidemstat therapy, meaning this patient received no other anticancer treatment while taking seclidemstat. While we recognize this is only a single patient, we believe it demonstrates drug activity in a patient with treatment-resistant Ewing sarcoma in a trial primarily designed to demonstrate safety, not efficacy. The momentum from these advances provides Solaris an opportunity to initiate and then complete, in August, a $6.2 million public offering. We are now applying these capital resources and the resources we continue to receive from the Cancer Prevention Research Institute of Texas to progressing our CECLADEN staff development program. I'd like to now discuss the development program. as well as the ongoing clinical trials in a bit more detail later. But at this time, I'd like to turn the call over to Mark Rosenblum for a brief review of Solaris' third quarter financial report. Mark, please go ahead.
You're reading a preview of the SLRX Q3 2020 earnings call.
Free account.
